What is a Local Safety Officer?

A Local Safety Officer (LSO) is an accountable operational resource located within a country, region or affiliate that translates global pharmacovigilance (PV) policy into compliant local practice. The LSO acts as the first line for adverse event intake, triage and local regulatory engagement; they provide clinical and operational inputs to the global safety network, maintain local inspection‑ready records and contribute to governance that enables the Qualified Person for Pharmacovigilance (QPPV) to meet legal obligations. LSOs are an extension, not a substitute, for central PV functions: legal responsibility for the overall PV system remains with the QPPV and the MAH (Marketing Authorisation Holder).

Purpose of the role

Global pharmacovigilance systems must reconcile uniform safety standards with diverse local legal requirements, healthcare systems and languages. LSOs operationalise this reconciliation by ensuring local adverse events are captured, assessed for seriousness and expectedness, and reported to the global safety database and the competent authority within jurisdictional timelines. They preserve data quality and traceability, support local regulatory dialogue, perform literature screening in local languages, and maintain inspection‑ready evidence demonstrating how local activities integrate with the global PV system. Effective LSO functions materially reduce regulatory and patient risk by ensuring timely, complete and well‑documented local safety actions.

Qualifications and competencies

An effective LSO typically has a healthcare or life sciences degree (e.g., pharmacy, medicine, nursing, MSc in life sciences); advanced clinical qualifications (PharmD, MD) enhance clinical assessment capability. Practical PV competence includes knowledge of ICH safety guidance (notably ICH E2A and ICH E2B), regional guidance such as EMA Good Pharmacovigilance Practices (GVP) Modules I and VI, and applicable national legislation (for example, country‑specific reporting obligations and electronic gateway requirements). Familiarity with safety databases (Argus, ARISg, Veeva, Oracle), MedDRA and WHO Drug Dictionary coding, literature screening tools and local regulatory portals is expected.

Experience expectations vary by company and risk profile, but a working LSO will typically have 2–4 years in safety or related roles and demonstrate clinical triage skills, case processing literacy, and competency in escalation and documentation. LSOs must be bilingual where local language proficiency is required for intake, correspondence and literature screening, and must complete initial PV induction and annual refresher training; inspection‑readiness training should be part of their annual learning plan. Organisations should record these requirements in job descriptions, delegation logs and the Pharmacovigilance System Master File (PSMF).

Responsibilities, timelines and operational workflows

LSO activities are defined by SOPs that map regulatory obligations to operational SLAs. Below, responsibilities are presented as integrated operational workflows with practical implementation details and inspection relevance. A concise responsibilities vs timelines table follows to aid inspection preparation and operational governance.

In practice, the LSO is responsible for continuous surveillance of intake channels (healthcare professionals, patients, literature, complaints, regulatory communications and digital channels). On receipt of information suggesting an adverse event, the LSO performs immediate triage: capture of minimum data (reporter identity and contact, patient identifier, suspect product, event description, outcome and dates) and clinical assessment of seriousness. For events that are life‑threatening, fatal, or imply hospitalisation, the LSO initiates urgent escalation by telephone and secure electronic notification to the Global Safety Lead and documents the time and method of notification. For routine intake, the LSO records the initial notification in a local intake register and creates or requests creation of the ICSR in the corporate safety database.

Case processing responsibilities encompass accurate data entry (patient demographics, event terms coded to MedDRA, suspect and concomitant drugs coded to WHO Drug Dictionary, seriousness and outcome), generation of narratives, and quality control. The LSO either enters the case directly into the central database (if authorised) or compiles and transmits a complete case package to the global case intake team within the company SLA. Missing essential information that would affect reporting obligations triggers a documented follow‑up plan: the LSO attempts clinical follow‑up with the reporter, documents each contact attempt in the follow‑up log, and updates the case in the database when new information is received.

LSOs must determine local expedited reporting obligations and coordinate local submissions. This requires applying national law to global case assessments: the LSO consults SOPs that cross‑map ICH and regional guidance (e.g., ICH E2A, EMA GVP Module VI) to local statutory timelines and submission portals. Practical implementation includes maintaining templates for local expedited reports, translation responsibilities, and procedures for data anonymisation and patient privacy in line with local data protection legislation. If a submission deadline is missed or ambiguous, the LSO escalates to Global Safety, Legal and Regulatory Affairs and documents the root cause and corrective action.

Literature screening in local languages is a recurring LSO duty. The LSO identifies predefined journals, conference proceedings and regulated local media, carries out screening at agreed frequencies, and submits any potential ICSRs or signal observations to the global signal management team using a standard capture template. Records of sources screened, search terms, dates and findings are retained for inspection.

LSOs serve as the local competent authority liaison. They acknowledge regulatory queries in accordance with local law and company SOPs, prepare responses with cross‑functional input (Medical, Regulatory, Quality, Legal), and ensure correspondence is retained in both the affiliate file and the PSMF. Inspection readiness demands a regulatory correspondence log that documents dates of receipt, acknowledgements, actions taken, and final responses.

Inspection support is a critical LSO obligation. The LSO maintains an inspection‑ready evidence set: role description, CV, training records, delegation log, intake and follow‑up logs, sample ICSRs representative of local activity, local submissions, literature screening records, KPI dashboards, governance meeting minutes and CAPA documentation. When an inspection notice is received, the LSO coordinates document collation, arranges local logistics, briefs accompanying personnel, and acts as a site subject matter expert. SOPs must address timelines for producing inspection packs, methods for redaction/anonymisation, and audit trails for documents provided to inspectors.

Quality monitoring, audits and governance are ongoing LSO contributions. LSOs perform periodic local case audits and desk reviews, report findings through the local safety committee and coordinate CAPAs with target timelines. They ensure training of local staff and keep records of PV awareness sessions. Continuity is assured through documented alternates, delegation updates and system access plans.

The practical responsibilities and corresponding operational timelines condensed here are provided in the following table to support both day‑to‑day management and inspection readiness.

SOPs should include explicit templates and examples for each of the items above (intake form, follow‑up log, literature capture template, regulatory submission checklist, inspection pack checklist). Practical implementation should also specify acceptable communication modes for urgent notifications (telephone call with contemporaneous e‑mail confirmation, secure messaging where permitted) and require screenshot or portal receipt capture for regulatory submissions.

Escalation and communication workflows

Escalation should be both time‑based and event‑based, with traceable auditable records. A commonly used escalation sequence begins at the LSO level for intake and triage, proceeds to the Local Medical or Local Safety Lead for clinical review and local regulatory liaison, escalates to the Global Safety Lead or Global Safety Physician for confirmation of global reporting obligations and database submission, and reaches the QPPV/Global Head of PV for decisions on global regulatory communication, signals and crisis management. Executive, Legal and Regulatory Affairs involvement is triggered when recall, withdrawal, public communication or litigation risk is identified. SOPs must define the circumstances for each escalation level, the maximum time to acknowledge each escalation, and the required documentation (phone log, e‑mail, incident report). Inspection teams will assess whether these escalation steps are followed in practice by reviewing time‑stamped records and interviewing staff.

Governance and organisational placement

LSOs most effectively operate under clear governance that delineates functional reporting lines, delegations and accountability. Functionally, LSOs often report to Local Medical Affairs or Regulatory Affairs for day‑to‑day matters while retaining an operational line to Global Safety/Global PV for safety‑specific activities. The delegation of tasks should be recorded in a delegation of authority log, signed by the QPPV or designated delegate; this log must make clear that delegation does not transfer statutory responsibility from the QPPV.

A Local Safety Committee — meeting monthly for high‑risk affiliates or quarterly in lower‑risk settings — provides structured governance. Committee agendas should include KPI review, open cases of note, regulatory correspondence, upcoming inspections, and CAPA tracking. Minutes with attendance and action owners are essential inspection artifacts.

Continuity planning requires that each affiliate nominates a trained alternate LSO, documents role handover procedures, ensures system access continuity (with secure role‑based access controls), and maintains emergency contact lists. The PSMF must be updated to reflect local arrangements, delegation logs and the identity and contact details of the LSO and alternates.

KPI definitions, targets and operational monitoring

KPIs provide objective evidence of local PV performance and support the QPPV’s oversight obligations. KPI selection and targets must be risk‑based, documented in governance materials and trended over time. Below is a concise table of core KPIs with practical definitions and suggested targets commonly acceptable to regulators and useful for inspection readiness. Organisations should calibrate targets based on product risk, local law and corporate risk appetite.

KPI monitoring requires a defined data source (safety database reports, intake logs, regulatory portal receipts), a frequency for dashboard refresh (monthly for active affiliates; quarterly for low activity), and an owner responsible for KPI validation. KPI definitions must be documented in the KPI SOP or a KPI definitions annex to the PSMF to ensure consistent interpretation during inspections.

Practical implementation details

Operationalising the LSO role requires pragmatic, auditable controls. Recommended practical steps include:

• SOP library: Maintain a minimal but comprehensive set of SOPs aligned to global standards: Local Safety Officer Responsibilities; AE Intake and Triage; Case Processing and Reporting; Escalation and Crisis Management; Literature Screening and Signal Reporting; Inspection Support; Local PV Audits and CAPA; Data Privacy and Anonymisation for PV.
• Templates and logs: Standardised intake forms, follow‑up logs, literature screening templates, regulatory submission checklists, escalation forms and inspection pack checklists to ensure consistency and ease of retrieval.
• Database access and controls: Role‑based access to the safety database; documented training certificates for database users; audit trails activated for case changes; procedures for backup and data retention consistent with local law.
• Training programme: Induction, annual refresher and inspection‑readiness modules; scenario‑based drills (mock intakes, mock inspections) at least annually; documented attendance and assessment.
• Communication protocols: Defined urgent notification routes (telephone + e‑mail), secure messaging options for PHI where permitted, and template language for regulatory acknowledgement and notifications.
• Audit and oversight: Local self‑inspection schedule with sample sizes based on case volumes (e.g., 10–20% of recent cases or a minimum number), escalation of findings to Local Safety Committee and Global PV, and documented CAPA plans with owners and timelines.
• Document retention: Retain PV records per local statutory requirements and global policy (typically several years post product expiry or as prescribed by national law). Maintain both electronic and hard‑copy local inspection folders as required.
• Change management: Formal process to update the PSMF, delegation logs and SOPs when roles change, responsibilities are reallocated, or systems are updated; capture training and communications related to the change.

These practical controls should be reflected in governance documents and are routinely reviewed by auditors and inspectors.

Regulatory context and inspection relevance

LSO SOPs and operational practices should be explicitly mapped to authoritative guidance. Key references that frequently underpin auditor and inspector expectations include:

• ICH E2A — Clinical Safety Data Management: Definitions and Standards for Expedited Reporting.
• ICH E2B(R3) — Data Elements for Transmission of Individual Case Safety Reports (ICSRs).
• EMA Good Pharmacovigilance Practices (GVP) — Module I (Pharmacovigilance System) and Module VI (Management and Reporting of Adverse Reactions).
• US FDA regulations (as applicable) — 21 CFR 312.32, 314.80, 600.80.
• WHO guidance on vaccine safety and regional pharmacovigilance resources.
• National competent authority guidance and portals (country specific).

During inspections, regulators focus on how local PV activities are integrated into the global system, whether roles and delegations are documented and respected, and whether evidence exists for timely reporting and governance. Inspectors will look for the LSO role description and delegation log, training records, intake and follow‑up logs, sample ICSRs documenting timelines from receipt to submission, literature screening records, KPI dashboards and governance meeting minutes. Recurrent inspection findings often include undocumented delegations, missing training evidence, incomplete intake logs, and insufficient documentation of follow‑up attempts; addressing these risks in SOPs and evidence repositories materially improves inspection outcomes.

Inspection readiness — evidence and practical tips

Create and maintain a local inspection folder (electronic and/or hard copy) that contains the following inspection‑centric evidence, indexed and cross‑referenced to the PSMF:

• LSO role description, CV and recent training certificates.
• Delegation of authority log with signatures and dates.
• Local intake log with timestamps, sample ICSRs and chain‑of‑custody for source documents.
• Copies of local regulatory submissions and portal receipts.
• Literature screening logs and examples of forwarded cases.
• KPI dashboard snapshots and trending graphs for the last 12 months.
• Minutes of Local Safety Committee meetings and action logs.
• Audit reports and current CAPA status with closure evidence.
• Inspection SOP and an inspection pack template ready to populate.
• Continuity plan and contact list including nominated alternates.

Additionally, conduct periodic mock inspections that simulate typical inspector requests (e.g., produce three recent serious ICSRs with documentation of triage, entry, escalation and local submission) and timetable exercises to validate the ability to produce documents within the SOP timeline.

Governance considerations and senior oversight

Senior oversight must ensure that local activities align with global PV strategy and regulatory compliance. The QPPV and Global Head of PV rely on local evidence to fulfil statutory oversight; therefore governance should include:

• Regular reporting from LSOs to Global Safety on KPIs, signals, regulatory interactions and inspection readiness.
• A standardised onboarding checklist and competency sign‑off for each newly appointed LSO.
• Periodic calibration sessions between Global Safety and LSOs to harmonise triage criteria, reporting thresholds and interpretation of local law.
• Executive oversight of high‑risk events with documented decisions and communication plans.
• Inclusion of LSO performance and local PV status in annual management review and the PSMF.

Why the role matters

By embedding appropriately qualified, trained and governed LSOs within affiliates, organisations ensure timely identification and reporting of safety information, preservation of high‑quality local records, and demonstrable compliance to inspectors. Effective LSOs reduce regulatory risk, enhance signal sensitivity through local intelligence, and strengthen the link between local clinical realities and global safety decision‑making.

References

• ICH E2A: Clinical Safety Data Management — Definitions and Standards for Expedited Reporting.
• ICH E2B(R3): Data Elements for Transmission of Individual Case Safety Reports (ICSRs).
• EMA — Good Pharmacovigilance Practices (GVP) Module I: Pharmacovigilance System and Module VI: Management and Reporting of Adverse Reactions.
• US FDA — 21 CFR Part 312.32, 314.80, 600.80 (safety reporting provisions).
• WHO — Global Vaccine Safety Blueprint and related pharmacovigilance guidance.
• CIOMS Working Group recommendations on safety surveillance (where relevant).

Last reviewed: June 2026